SoFi CEO enters prepaid forward contract on 1.5 million shares
In a recent transaction reported to the Securities and Exchange Commission, Greg Keenan, the Chief Medical (TASE:BLWV) Officer of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), sold 12,239 shares of the company’s common stock. The shares were sold on March 3, 2025, at an average price of $8.00 per share, totaling $97,912. The company, currently valued at $1.1 billion, has demonstrated robust revenue growth of 34% over the last twelve months and maintains a healthy current ratio of 4.6x.
Earlier, on February 28, 2025, Keenan acquired 62,583 shares of common stock at no cost, as part of a performance rights plan. Additionally, he was granted employee stock options for 95,570 shares, exercisable at a price of $7.55 per share, with an expiration set for February 28, 2035.
These transactions reflect Keenan’s ongoing involvement with Aurinia Pharmaceuticals, where he maintains a significant stake, holding 161,789 shares following these activities.
In other recent news, Aurinia Pharmaceuticals reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of $0.01, which did not meet analysts’ expectations of $0.03. The company’s revenue for the quarter was also below forecasts, reaching $59.9 million against a projected $61.7 million. Despite these shortfalls, Aurinia experienced significant growth over the year, with total revenue increasing by 34% to $235.1 million. The company’s flagship product, LUKINIS, reported net product sales of $216.2 million for the year, marking a 36% increase from 2023. Looking ahead, Aurinia has set a total revenue guidance for 2025 in the range of $250 million to $260 million, with net product sales expected to range from $240 million to $250 million. The company is also advancing its pipeline, particularly with the development of AUR200. Additionally, Aurinia Pharmaceuticals is preparing for potential generic competition, emphasizing its commitment to defending its intellectual property rights for LUKINIS. These developments highlight the company’s ongoing efforts to expand its market presence and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.